Thankfully, some progress has been made in the last couple of years. In 2018, the World Health Organization (WHO) issued new treatment recommendations for Hr-TB, replacing the previous 9-month course of rifampicin, pyrazinamide, and ethambutol (RZE) with a 6-month regimen based on levofloxacin plus RZE [5, 6] . This recommendation is reflected in the updated guideline for DR-TB jointly released in 2019 by the American Thoracic Society, Centers for Disease Control and Prevention, European Respiratory Society, and Infectious Disease Society of America, which also suggests reducing the duration of pyrazinamide to 2 months in case of noncavitary and lower-burden disease or if a high risk of pyrazinamideinduced toxic effects are anticipated [7] .
However, high-TB-burden countries will struggle to routinely implement these new guidelines for Hr-TB because easy access to INH-resistance testing is a challenge. Although there are WHO-endorsed technologies (such as line-probe assays and liquid cultures) that can detect INH resistance, these tools are limited to centralized or reference laboratories [8] . Also, even in settings where the prevalence of Hr-TB is the highest, starting a quinolone-containing regimen empirically requires caution, in spite of the low levels of resistance to levofloxacin and/or pyrazinamide, as documented by a recent surveillance project [9] .
The year 2020 might bring some hope, as the Xpert MTB/XDR cartridge (Cepheid, Sunnyvale, CA, USA) is expected to be released and will include resistance testing for INH, fluoroquinolones, and second-line injectables [10] . The TB diagnostics pipeline also includes several next-generation, high-throughput molecular tests that are able to simultaneously detect rifampicin and INH resistance in centralized laboratories [11, 12] .
Whole-genome sequencing (WGS) data continue to shed light on the wide range of mutations associated with drug resistance, thus not only improving our understanding of transmission dynamics but also helping to refine therapeutic choices for the individual patient [13] . Importantly, a deeper examination of the genotypic diversity of INH resistance would be of great benefit to inform treatment guidelines that are currently based on low-quality evidence [6] . At present, nationwide scale-up of WGS for routine TB diagnosis may not seem within reach in most high-TB-burden countries owing to cost and infrastructure requirements. However, this technology is becoming cheaper and easier and offers an incredible opportunity to generate better quality information on INH resistance, thanks to its ability to detect clinically relevant mutations that are not captured by conventional rapid tests, which usually target only the most common katG and inhA mutations [13, 14] . Recently, Unitaid and the Foundation for Innovative New Diagnostics (FIND) have partnered to launch the Seq&Treat project that will pilot next-generation genome sequencing, an innovation that will enable fast, accurate diagnosis of DR-TB [15] .
Beyond technologies and guidelines, we need to acknowledge the human impact of DR-TB, which imposes a tremendous physical, mental, financial, and social burden on patients. In addition to the 3 million TB patients who fail to get diagnosed or notified [11] , there are large numbers of people with Hr-TB who are misdiagnosed and consequently mismanaged. Therefore, access to quality TB care is a human rights issue. In 2020, quality TB care must include universal DST-not just RR testing-for all individuals with TB, followed by individualized therapy, based on DST results.
